Results 161 to 170 of about 7,402 (232)

Intravenously injected Newcastle disease virus in non-human primates is safe to use for oncolytic virotherapy

, 2014
Pascal Buijs, Geert van Amerongen, Stefan van Nieuwkoop, Theo M. Bestebroer, Peter R. W. A. van Run, Thijs Kuiken, Ron A. M. Fouchier, Casper H.J. van Eijck, Bernadette G. van den Hoogen   +8 more
openalex   +1 more source

Enhanced Sensitivity of Patient-Derived Pediatric High-Grade Brain Tumor Xenografts to Oncolytic HSV-1 Virotherapy Correlates with Nectin-1 Expression [PDF]

, 2018
Gregory K. Friedman, Joshua D. Bernstock, Dongquan Chen, Li Nan, Blake P. Moore, Virginia Kelly, Samantha Youngblood, Catherine P. Langford, Xiaosi Han, Eric Ring, Elizabeth A. Beierle, G. Yancey Gillespie, James M. Markert   +12 more
openalex   +1 more source

The 16th International Oncolytic Virus Conference: Advancing oncolytic virotherapy by balancing anti-tumor and anti-viral immunity. [PDF]

Mol Ther Oncol
Stavrakaki E, Everts A, van den Hoogen BG, Lamfers MLM.   +3 more
europepmc   +1 more source

Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy. [PDF]

J Transl Med, 2023
Wang X, Shen Y, Wan X, Hu X, Cai WQ, Wu Z, Xin Q, Liu X, Gui J, Xin HY, Xin HW.   +10 more
europepmc   +1 more source

Oncolytic virotherapy in glioblastoma patients induces a tumor macrophage phenotypic shift leading to an altered glioblastoma microenvironment [PDF]

, 2018
Wouter van den Bossche, Anne Kleijn, Charlotte E. Teunissen, Jane S. A. Voerman, Cristina Teodósio, David P. Noske, Jacques J. M. van Dongen, Clemens M.F. Dirven, Martine L.M. Lamfers   +8 more
openalex   +1 more source

Clonal variation in interferon response determines the outcome of oncolytic virotherapy in mouse CT26 colon carcinoma model

, 2014
Janne Ruotsalainen, Minna U. Kaikkonen, Minna Niittykoski, Miika Martikainen, Chantal G. Lemay, Julie A. Cox, N S De Silva, Agnieszka Kuś, Theresa Falls, Jean‐Simon Diallo, Fabrice Le Bœuf, John C. Bell, Seppo Ylä‐Herttuala, Ari Hinkkanen, Markus Vähä‐Koskela   +14 more
openalex   +1 more source

Oncolytic Virotherapy for Relapsed, IDH-Mutant, Grade 3 Astrocytoma: A New Promising Approach - A Case Report. [PDF]

Case Rep Oncol
Gesundheit B, Srinivas Raju J, Brauns CY, Weisslein C, Schmoll H, Ellis R, Posen Y, Schmitz A, Sahinbas H.   +8 more
europepmc   +1 more source

IDH1 mutation impairs antiviral response and potentiates oncolytic virotherapy in glioma. [PDF]

Nat Commun, 2023
Chen X, Liu J, Li Y, Zeng Y, Wang F, Cheng Z, Duan H, Pan G, Yang S, Chen Y, Li Q, Shen X, Li Y, Qin Z, Chen J, Huang Y, Wang X, Lu Y, Shu M, Zhang Y, Wang G, Li K, Lin X, Xing F, Zhang H.   +24 more
europepmc   +1 more source

The 15th International Oncolytic Virotherapy Conference: Clinical successes point to a brighter future for cancer treatment

Molecular Therapy: Oncology
The 15th International Oncolytic Virotherapy Conference took place in Banff, Alberta, and showcased diverse new approaches to enhancing oncolytic virus therapy. A reflective keynote highlighted industry challenges and lessons.
Jahanara Rajwani, Danyel Evseev, Esha S. Kaul, Douglas J. Mahoney   +3 more
doaj  

Targeting tumor vasculature through oncolytic virotherapy: recent advances

, 2015
Jaime R. Merchan, Marcela Toro Bejarano
openalex   +2 more sources